Positive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinson’s disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 Cash, cash equivalents and marketable securities balance of $209.0M as of June 30, 2025 expected to fund planned operat ...

Core Insights - The study successfully established the safety and tolerability of VTX3232 in patients with early-stage Parkinson's disease, with no drug-related treatment-emergent adverse events reported [1][2] - VTX3232 demonstrated significant reductions in NLRP3-related biomarkers in both cerebrospinal fluid (CSF) and plasma, indicating sustained target engagement [1][3] - The company plans to initiate a placebo-controlled Phase 2 trial for VTX3232 in Parkinson's disease and potentially in other neurodegenerative disorders like Alzheimer's disease [3][6] Study Details - The Phase 2a study evaluated a 40mg oral daily dose of VTX3232 in ten patients over a 28-day treatment period, focusing on safety and tolerability [3][4] - Key secondary objectives included pharmacokinetic profiling and measuring effects on biomarkers of NLRP3 inhibition, with significant reductions observed in IL-1, IL-6, and hsCRP [3][4] - The study showed that VTX3232 maintained plasma and CSF levels above the IC90 for IL-1b for 24 hours [3][9] Biomarker Findings - VTX3232 treatment resulted in reductions of biomarkers such as IL-1β, IL-18, IL-6, and hsCRP, with some approaching the limit of quantitation [9] - Statistically significant improvements were noted in motor and non-motor symptoms of Parkinson's disease, as measured by MDS-UPDRS [9] - No acute changes were observed in exploratory PET imaging, consistent with the short duration of the study [9] Future Development - Ventyx intends to present the complete dataset at a future medical meeting and publish full results in a peer-reviewed journal [5] - The company is also conducting a 12-week Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline results expected in H2 2025 [1][8] - Planning for a double-blind, placebo-controlled, dose-ranging Phase 2 trial in Parkinson's disease is underway [6]

Company Overview - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases [3] - The company leverages expertise in medicinal chemistry, structural biology, and immunology to discover differentiated oral small molecule therapeutics for conditions with high unmet medical need [3] Product Pipeline - Ventyx's portfolio includes NLRP3 inhibitors such as VTX2735, which is in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases [4] - The inflammatory bowel disease portfolio features two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor [4] Upcoming Events - Company executives will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025, from 12:50 to 1:20 PM ET [2] - A webcast of the event will be available on the Ventyx website, with a replay accessible for ninety days post-event [2]

Core Insights - Ventyx Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases [8] Pipeline Updates and Anticipated Milestones - Ventyx is advancing two novel NLRP3 inhibitors, VTX3232 and VTX2735, through Phase 2 trials targeting neurodegenerative, cardiovascular, and metabolic diseases [2] - The Phase 2 biomarker trial for VTX3232 in Parkinson's disease is expected to complete in Q2 2025, with key endpoints including safety and pharmacokinetics [3] - Results from the Phase 2 trial of VTX3232 in obesity and cardiometabolic risk factors, as well as VTX2735 in recurrent pericarditis, are anticipated in the second half of 2025 [3][4] Financial Overview - As of March 31, 2025, Ventyx reported cash, cash equivalents, and marketable securities of $228.8 million, sufficient to fund operations into at least H2 2026 [11][17] - Research and Development (R&D) expenses for Q1 2025 were $22.9 million, down from $33.7 million in Q1 2024 [11] - General and Administrative (G&A) expenses decreased to $7.2 million in Q1 2025 from $8.0 million in Q1 2024 [11] - The net loss for Q1 2025 was $27.4 million, compared to a net loss of $38.6 million in Q1 2024 [11][15] Inflammatory Bowel Disease (IBD) Portfolio - Ventyx's IBD portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor [9] - Tamuzimod has shown robust clinical and endoscopic remission rates compared to placebo, positioning it as a potential backbone for future combination therapies in ulcerative colitis [11] - VTX958 demonstrated a dose-dependent endoscopic response in Crohn's disease, suggesting potential disease-modifying benefits [11]

Core Insights - Ventyx Biosciences has appointed seven internationally recognized experts to its Scientific Advisory Board (SAB), enhancing its leadership in the NLRP3 inflammasome research and development [1][2][3] Group 1: Appointment of SAB Members - The new SAB members have significant expertise in NLRP3 inflammasome research and its implications in neurodegenerative and cardiometabolic diseases [2][3] - The expanded SAB will provide guidance in the clinical development of Ventyx's oral NLRP3 inhibitors, particularly in Phase 2 studies for Parkinson's disease and other conditions [3][4] Group 2: Company Development and Research Focus - Ventyx is focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, leveraging its expertise in medicinal chemistry and immunology [11][12] - The company is advancing two lead NLRP3 inhibitors, VTX2735 and VTX3232, through Phase 2 trials, with topline data for VTX3232 in Parkinson's disease expected in Q2 2025 [4][12]